Roxime-CV 625 Tablet
Marketer
Strio Healthcare
Salt Composition
Cefuroxime (500mg) + Clavulanic Acid (125mg)
Overview Roxime-CV 625 Tablet
Combiflox 625mg tablets combat diverse bacterial infections by inhibiting microbial proliferation and spread. This prescription medication should be taken precisely as directed. Consumption with or without food is acceptable, but consistent timing optimizes effectiveness. Exceeding the prescribed dosage is harmful. If a dose is missed, take it immediately upon recall. Complete the entire course of treatment, even with symptom improvement; premature cessation may compromise efficacy. Common side effects include nausea, vomiting, diarrhea, and dyspepsia. Severe side effects necessitate immediate medical attention. Allergic reactions (rash, itching, swelling, dyspnea) require urgent medical care. Inform your physician about all current medications before commencing treatment. Pregnant or lactating individuals require medical consultation prior to use. Alcohol consumption should be avoided due to potential increased drowsiness. While it typically doesn't impair driving, refrain from driving if drowsiness or dizziness occurs. Adequate rest, a nutritious diet, and sufficient hydration promote faster recovery. Your doctor may order lab tests to monitor the medicine's effects.
Primary Ingredients of Roxime-CV 625 Tablet
No text provided to rephrase.
Uses of Roxime-CV 625 Tablet
Managing bacterial infections
Major Benefits of Roxime-CV 625 Tablet:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Roxime-CV 625 Tablets can be consumed with or without food, although consistent timing is recommended.
Common Side effects of Roxime-CV 625 Tablet:
- Nausea
- Vomiting
- Diarrhea
- Increased liver enzymes
- Allergic reaction
How to use Roxime-CV 625 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Roxime-CV 625 Tablet whole; avoid chewing, crushing, or breaking it. Consumption with or without food is acceptable, though consistent timing is recommended.
How Roxime-CV 625 Tablet works:
Cefuroxime and Clavulanic Acid, combined as Roxime-CV 625 Tablet, offer a dual-action approach to bacterial infections. Cefuroxime, an antibiotic, disrupts bacterial cell wall synthesis, a crucial process for bacterial viability. Clavulanic Acid, a beta-lactamase inhibitor, neutralizes bacterial enzymes that would otherwise degrade Cefuroxime. This synergistic effect broadens Cefuroxime's effectiveness and overcomes bacterial resistance mechanisms.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Roxime-CV 625 Tablet and alcohol consumption.
PregnancySAFE IF PRESCRIBED
Pregnancy use of Roxime-CV 625 Tablet is generally deemed safe. Preclinical trials in animals revealed minimal or no harm to fetuses; data from human trials, however, remain scarce.
Breast feedingSAFE IF PRESCRIBED
The medication Roxime-CV 625 Tablet is considered safe for breastfeeding mothers. Research in humans indicates negligible transfer of the drug into breast milk, posing no apparent risk to the infant.
DrivingNOT RELEVANT
Inapplicable, since Roxime-CV 625 Tablets are prescribed solely for inpatients.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding Roxime-CV 625 Tablet's use in individuals with renal impairment. Physician consultation is recommended.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding Roxime-CV 625 Tablet use in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Roxime-CV 625 Tablet :
Should you forget a Roxime-CV 625 Tablet dose, take it immediately if you remember. If, however, your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Roxime-CV 625 Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Treatment | Anti-infective agents |



